Results 41 to 50 of about 19,015 (246)
Semaglutide as Treatment for Obesity in Adolescents [PDF]
Background: Semaglutide was recently approved to treat obesity in adolescents. Main objective: To provide a critical appraisal of semaglutide as anti-obesity agent in adolescents. Methods: Pubmed search up to May 19, 2023.
Mikhail, Nasser, Wali, Soma
core +2 more sources
Diabeedi ravi ja kardiovaskulaarne risk [PDF]
Eesti Arst 2016; 95(10):667 ...
Roosimaa, Mart
core +2 more sources
Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi +7 more
wiley +1 more source
Effects of pH and Salts on the Aggregation State of Semaglutide and Membrane Filtration Performance
The hydrophobic region of semaglutide makes it prone to aggregation in aqueous solution, which leads to serious interception in microfiltration. The influences of pH and low concentrations of salts (NaCl, CH3COONa, Na2SO4 and (NH4)2SO4) on the particle ...
Lei Duan +4 more
doaj +1 more source
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie +5 more
core +1 more source
An oral nanoplatform, MOP@T@D, which can maintain glucose homeostasis and restore islet β cells in diabetic rats is developed. It achieves efficient intestinal absorption and liver‐targeted delivery. The nanoparticle disintegrates only in response to hyperglycemia to release insulin on demand and provides antioxidant protection through selenoprotein ...
Chenxiao Chu +14 more
wiley +1 more source
Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging [PDF]
Background: Glucagon-like peptide-1 receptor agonists may be a treatment option in patients with non-alcoholic fatty liver disease (NAFLD). Aims: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non ...
Andersen, Grit +8 more
core +1 more source
Liquid crystalline inverted lipid phases and reverse micelles are self‐assembled lipid nanostructures that enhance the solubility, stability, and delivery of diverse therapeutics. This review integrates their physicochemical principles, formulation strategies, drug loading mechanisms, and biomedical applications, highlighting their growing ...
Numan Eczacioglu +3 more
wiley +1 more source
By profiling the spatiotemporal hepatic landscape of CHB mouse models, the originally peri‐portal localized KCs migrated to the peri‐central in a CXCL9‐CXCR3‐dependent manner, facilitating their interaction with HBV+ hepatocytes. The interaction promoted LMD in KCs through ASGR1‐induced LXRα degradation, which, in turn, induced CSC formation via Stat3 ...
Jingqi Shi +18 more
wiley +1 more source
PurposeThis study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2
Zeyu Xie +4 more
doaj +1 more source

